NEW YORK, NY / ACCESS Newswire / July 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Altimmune, Inc. ("Altimmune, Inc.") (NASDAQ:ALT) concerning possible violations of federal securities laws. Altimmune announced topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), revealing that the […]

NEW YORK, NY / ACCESS Newswire / July 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of KBR, Inc. ("KBR, Inc.") (NYSE:KBR) concerning possible violations of federal securities laws. "HKBR issued a press release on June 20, 2025, announcing that omeSafe Alliance, a KBR . . . Joint Venture,

(NASDAQ:MSGY), Hong Kong, July 07, 2025 (GLOBE NEWSWIRE) — Masonglory Limited (the “Company”), is a Hong Kong based subcontractor providing wet trades and related ancillary services to private and public sectors, today announced the pricing of its initial public offering (the “Offering”) of 1,500,000 ordinary shares (the “Ordinary Shares”) at a public offering price of

Over 70 Speakers Including Illinois Governor JB Pritzker, IBM CEO Arvind Krishna,NYU Professor Scott Galloway and Technology Journalist David Pogue to Take Part in Inaugural Forum Exploring Quantum Policy and Quantum's Impact On Energy Innovation, AI, Security, Healthcare, and Investment P33,Intersect Illinois and theChicago Council on Global Affairs today announced the inauguralGlobal Quantum Forum, a

Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, all dates inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc.,

(NASDAQ:SRPT), NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline. SO WHAT: If

Pharmaceutical companies have made significant investments in traumatic brain injury drug development, although the late-stage pipeline remains limited. However, several early-phase clinical trials are ongoing, with promising mid- and late-stage trial results expected to expand the traumatic brain injury therapeutic market in the coming years. Historically, moderate-to-severe traumatic brain injuries have been the focus of

Sagent Pharmaceuticals (“Sagent”), a leading provider of pharmaceuticals to the US market, and Qilu Pharmaceutical Co., Ltd. (“Qilu”), a leading vertically integrated pharmaceutical company based in China, today announced a strategic collaboration to commercialize a portfolio of complex injectable products for the US market. https://mma.prnewswire.com/media/2726068/Sagent_Logo.jpg Through this partnership, Sagent will have exclusive rights to commercialize

(TSX:HUT),(NASDAQ:HUT), MIAMI, July 07, 2025 (GLOBE NEWSWIRE) — Hut 8 Corp. (Nasdaq | TSX: HUT) (“Hut 8” or the “Company”), an energy infrastructure platform integrating power, digital infrastructure, and compute at scale to fuel next-generation, energy-intensive use cases such as Bitcoin mining and high-performance computing, today announced it will release financial results for the second

(NASDAQ:FTRE), NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fortrea Holdings, Inc. (NASDAQ: FTRE) between July 3, 2023 and February 28, 2025, both dates inclusive (the “Class Period”), of the important August 1, 2025 lead plaintiff deadline. SO WHAT: If